Prostate cancer patients with rising PSA whilst on first-line androgen deprivation therapy ( ADT ) were randomised ( 1:1 ) in a double-blind trial to receive bicalutamide 50mg plus placebo or bicalutamide 50mg plus dutasteride 3.5 mg once daily for 18 months .